InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.59
(
-0.16%
)
US TECH 100
19,226.00
(
-0.17%
)
Dow Jones
39,250.54
(
0.30%
)
Brent Oil
85.16
(
0.18%
)
Bitcoin
63,976.32
(
-1.30%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jaybe

Send PM Follow Ignore
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

jaybe

Re: bellweather1 post# 28849

Monday, 04/08/2013 8:06:37 AM

Monday, April 08, 2013 8:06:37 AM

Post# of 80490
The most comprehensive guidelines come from NCCN...

Also referenced on page 3 of the RengenceRx piece.

See link for summary of NCCN guidelines, check out page 12, where Pona is recommended first for all mutuations. Ponatinib summary on pages 20-26. I like the summary slide, page 26, "[Ponatinib is]expected to significantly improve outcomes of CML and Ph+ ALL".

(By the way if you want to see what a dirty drug profile looks like check out Bosutinib on page 16.)


https://winshipcancer.emory.edu/media/file/2013%20Nursing%20Symposium/Nikki%20Wilson%20-%20Novel%20Therapies%20for%20the%20Treatment%20of%20Multiple%20Myeloma%20and%20Leukemia.pdf
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up